Standard Template for a Candidate Demonstration Project · Standard Template for a Candidate...
Transcript of Standard Template for a Candidate Demonstration Project · Standard Template for a Candidate...
Standard Template for a Candidate Demonstration Project
Note: the questions with asterisk should be filled.
1.* Title of the project:
ANDI as the regional coordination mechanism for demonstration projects and product
R&D in Africa
2.* Submitted by:
3.* Target disease or health condition:
(Focus on type II and III diseases and special R&D needs of developing countries in type I diseases where there is an identified health technology gap.)
The proposal focuses on the coordination and financing of R&D for types II and III
diseases and special R&D needs of developing countries in type I diseases in Africa.
4.* The suggested health technology that project seeks to develop:
(e.g. medicine; diagnostic test; medical device; vaccine etc.) The proposal seeks to leverage existing ANDI structure to develop and promote access to
medicines, diagnostic tests, medical devices, and other technologies for type II, III and special
needs of developing countries in type I diseases, where there is a gap, need and opportunity. In
addition, ANDI will use its global network of partners to implement essential technology
platforms for R&D, such as the development and access to novel classes of compound library
based on traditional medicines and natural products, technology evaluation platforms, open
source databases and access to critical R&D facilities and equipment etc. ANDI have relevant
experience and track record in R&D program coordination, pre-competitive project
identification, selection and financing in Africa. It has established a broad network of African
and international institutions (public and private), exemplified by the 38 pan African Centres of
Excellence implemented by ANDI as well as South South and North South partnerships in
various R&D and manufacturing areas.
5.* Project summary:
We propose to leverage the existing ANDI structure as a coordination, financing,
monitoring and evaluation platform for demonstration projects and the sustained implementation
of R&D in Africa. Similar mechanism can be deployed in other regions. This innovative and
sustainable approach will: i) manage and oversee the implementation of demonstration and other
R&D projects that meet the needs of developing countries, ii) fundraise and disburse funds for
projects, iii) implement call for proposal, as required, to ensure optimal portfolio balance and
delivery of milestones, iv) develop and utilize open source and technology platforms in support
of projects, and access to critical equipment, v) coordinate the establishment of local and global
partnerships, networks, technology transfer and capacity building in support of demonstration
projects.
ANDI have a track record in the coordination of health R&D and associated capacity building in
Africa: i) It has implemented the identification and recognition of the first set of 38 pan-African
CoEs (public and private entities) in health innovation based on criteria and an open call for
proposals (1). These CoEs will support implementation of specific R&D and capacity building
activities as well as South South and North South partnerships in Africa; ii) it has successfully
implemented the identification and initiation of viable projects through call for proposals, with
hundreds of proposals received and evaluated. An independent ANDI Scientific and Technical
Advisory Committee (STAC) supports these processes. Some projects selected and funded
include the evaluation and technology transfer of an affordable medical device suite for maternal
and child health in Africa and co-formulation of a combination therapy to treat sickle cell
anemia. Also, a number of network or consortium projects were identified, including a disease
monitoring and surveillance network, diagnostics/medical device networks, and a traditional
medicines and natural products network.
ANDI will proactively identify additional partners to support projects and ensure that project
milestones are met and projects are successfully transitioned from one phase to another. An
important part of this project will be the development of ANDI KnowledgeBase to support the
management of demonstration projects and promote information sharing, in manner that adds
value and supports open innovation (Figure 1). This database will also support the proposed
R&D observatory agreed by the World Health Assembly (WHA66.22).
Figure 1: ANDI Knowledge database concept with an open access and closed space.
Another example of an innovative and much needed technology platform that will be
implemented and made available by ANDI is an annotated compound library of traditional
medicines and natural products from African biodiversity that can support screening campaigns
and reverse pharmacological evaluations. ANDI is already discussing with partners in other
regions to establish and use such resource widely. Such resource will support the development of
new medicines for infectious diseases, including those caused by drug resistant bacterial
pathogens that are prevalent in developing countries and for which new drugs are lacking
(example diarrheal, respiratory infections and TB). The resultant leads from the screens for
bacterial pathogens can be developed by ANDI and relevant global partnership. ANDI is also
working with regional and global partners to establish the much needed novel diagnostics
development and evaluation platforms.
Consistent with the vision of ANDI as well as objectives of the GSPoA and demonstration
projects (WHA66.22, 2013), any sustainable solution to the health challenges of developing
countries especially the African continent must strengthen their R&D foundation and capacity
for innovation and entrepreneurship. Through this project, ANDI will work with partners in
Africa and overseas to create sustainable, scalable, and transformative products as measured by:
Access to quality and much needed medicines, diagnostics/medical devices and vaccines.
Training of individuals and institutions to achieve competitiveness.
(Approximately 500 words)
6.* Public health need that the proposed project aims to address:
(Explain the public health need in terms of burden of disease; prevalence; incidence; fatality rate; geographical spread; current interventions and their limitations; and what proposed new technology would change in terms of disease prevention, control, diagnosis, treatment etc. If detailed information is not possible at present then please provide some basic level information)
The African continent, particularly sub-Saharan Africa, bears the greatest burden of types
II and III diseases including the so called neglected diseases, malaria, tuberculosis, HIV/AIDs,
diarrheal and respiratory diseases in the world (2 - 4). While substantial progress has been
achieved in Africa in reducing years of life lost due to premature mortality (YLLs) from
communicable, maternal, neonatal, and nutritional causes, these conditions still account for three
out of four premature deaths (5). In terms of non-fatal health outcomes from diseases and
injuries, the leading causes of years lived with disability (YLDs) in sub-Saharan Africa are
neglected tropical diseases (schistosomiasis, onchocerciasis, African trypanosomiasis, and
hookworm). At the same time, a double burden of communicable and non-communicable disease
now characterizes the health profile in sub-Saharan Africa. However, there are few
mechanisms in place in Africa to ensure sustained access to the tools needed to control,
diagnose or treat these diseases. The over dependence on externally developed and
procured health products is unsustainable and insufficient to meet local needs.
Over the past years, various development agencies in Europe, North America, Japan as well as
philanthropic foundations and international organizations, have supported both capacity-building
and institutional strengthening of clinical laboratories in Africa. Unfortunately, some of these
capacities have not been systematically leveraged to support the health product R&D needs of
Africa in a sustainable way.
A detailed landscape analysis undertaken by ANDI shows that, capacity for innovation exist in
Africa but that the key challenges include lack of coordination of ongoing efforts, lack of
funding and lack of collaboration among African institutions. There is an urgent need for
transformative approaches that address these challenges within Africa, in a manner that
strengthens North South and South South collaboration, and translate stagnating African
discoveries into usable and accessible health tools (4, 6, 7). A recent Lancet article by Pedrique
et al. 2013, show that of the 850 new therapeutic products (drugs, vaccines, biological)
registered from 2000 to 2011, only 4% were indicated for neglected diseases, including
malaria, TB, HIV/AIDS, diarrhea and others. This finding suggests a persistent insufficiency in
drug and vaccine development for Types II and III. Therefore, our proposal addresses a critical
public health need and presents an innovative and coordinated approach to R&D and access to
health interventions in Africa.
Approximately 400 words
7.* Explain which new and innovative approaches and mechanisms to supporting
financing and coordination of R&D this project would demonstrate? (This is a very important part to be filled. The idea of these demonstrations projects is
“to address identified gaps that disproportionately affect developing countries, particularly the poor, and for which immediate action can be taken” (WHA66.22).
66th WHA considered these demonstration projects as part of the efforts to “take forward action in relation to monitoring, coordination and financing for health research and development”. The assembly decided to identify such projects that: “(a) address identified research and development gaps related to discovery, development and/or delivery, including promising product pipelines, for diseases that disproportionally affect developing countries, particularly the poor, and for which immediate action can be taken; (b) utilize collaborative approaches, including open-knowledge approaches, for research and development coordination; (c) promote the de-linkage of the cost of research and development from product price; and (d)
propose and foster financing mechanisms including innovative, sustainable and pooled funding; (2) The demonstration projects should provide evidence for long-term sustainable solutions.”)
This proposal addresses the urgent need for innovative and transformative approaches
for coordination and financing of R&D for diseases that disproportionately affect developing
countries through the use of the African-based network and global North South and South South
partnership. This concept is new, inclusive and can be extended to other regions with close
collaboration with existing initiative, such as TDR, PDPs, EDCTP. The approach is amenable to
global oversight, including through WHO. ANDI brings with it established processes and is best
placed to support the management/coordination function for product R&D projects in Africa.
The immediate benefits of leveraging ANDI as the coordination mechanism are:
(i) ANDI offers a mechanism to develop a long-term and sustainable solution for the support of R&D within Africa.
(ii) ANDI is familiar with identified research and development gaps related to discovery,
development and/or delivery, including promising product pipelines, for diseases that
disproportionally affect developing countries, both in Africa and globally for which
immediate action can be taken;
(iii) ANDI understands and have supported various collaborative approaches, including
open-knowledge and networked approaches for research and development
coordination as well as product development partnerships;
(iv) ANDI has established a mechanism to promote the de-linkage of the cost of R&D
from product price.
As part of the development of the strategic business plan for ANDI, a proposal was made to
establish an African Innovation Fund (AIF) at the African Development Bank (AfDB) to support
health R&D and access in Africa. Although the AIF has not been implemented, the concept is
very relevant to the current discussion on options for financing R&D for diseases that
disproportionately affect developing countries. Such fund can house a pooled or special fund
from taxes for health R&D and access, from which demonstration and future health R&D
projects can be financed. The fund can also be managed through a Trust Fund held by WHO or
other international/regional bodies but fund disbursement to projects can be implemented as part
of the project coordination mechanism. More importantly, such fund can be managed as a self-
sustaining Social Venture Fund that can be divided into two parts: i) a grant making part that
could fund R&D and product registration, e.g. WHO prequalification, and ii) a second portion
with modest loaning modality to support the manufacture and large scale production of products
emanating from these projects. This later part can also support things like technology transfer,
South South or North South partnerships that seek to implement joint venture entities for the
local production and distribution of such products in Africa. This approach will ensure the de-
linkage of cost of R&D from the cost of final product.
A schematic representation of this de-linkage of R&D from the cost of final product is
presented in Fig 2.
(Approximately 400 words)
8.* Evidence of market failure/research landscape:
(Explain why there has been no investment in this technology or why investment has not resulted in access to the health care product.) Market failure for type II and III diseases is well documented (8), and the Global Strategy
and Plan of Action (GSPoA), outlined at the 61st World Health Assembly provides a framework
to drive health product innovation in a sustainable way (9). A key element of this strategy is the
formation of collaborative R&D mechanism in disease endemic countries that ensure that
Figure 2: different mechanisms employed by ANDI for managing and financing upstream R&D, the critical transition from R&D to manufacture and the downstream manufacture/access. Donor funding through grant making is suitable for upstream R&D for diseases that disproportionately affect developing countries but manufacture and access require a mixture of financing mechanism and incentives. Close coordination are required in all cases.
existing capabilities are leveraged, identified gaps are more effectively filled and local priorities
drive the R&D agenda.
An African health R&D landscape analysis undertaken to inform the establishment of ANDI (4,
6) show that there is significant research gap, for example, only few products are being
researched or in clinical trials for the Continent’s most prevalent diseases (Figure 3). Second,
there is a little collaboration between biomedical R&D centers across Africa. Only 5% of peer-
reviewed articles published from 2004-2008 involved institutions in more than one African
country. Thirdly, there is insufficient investment in African R&D with overall yearly R&D spend
of 0.3% of total African GDP, which is about USD 14 billion below the world median (4, 6).
Also important is a lack of coordination of ongoing efforts, including fragmented financing in
the continent (1). Pedrique et al. 2013, demonstrated a persistent insufficiency in drug and
vaccine development for Types II and III. There are promising trends that can be harnessed to
address these challenges: there is capacity along the health product R&D value chain across
Africa as evidenced by published articles, patents granted, clinical trial competence and
pharmaceutical manufacturing capacity. These show that what is indeed missing is a coordinated
effort and investment in Africa to overcome the identified challenges. Therefore, our proposal
addresses a critical public health need and presents an innovative approach to R&D in Africa.
Figure 3: Number of research articles and clinical trials
(Approximately 200 words)
9. The scientific and technical feasibility: (Describe the scientific and technical basis for the proposed technology in terms of the state of the art e.g. candidate molecules; biomarkers; pipeline; previous efforts, if any, to develop same or similar technology etc. Include some risk analysis)
This proposal is not focusing on a specific candidate molecule or technology, but it is
seeking to manage and coordinate the development of a pipeline of relevant products and
technologies that emanate from Africa, including approved demonstration projects and to make
these technologies more likely to deliver agreed products. This approach also supports the
development of a diversified portfolio that provides opportunity for cross learning from multiple
projects, diseases and implementing partners. ANDI has the track record and experience in
implementing similar efforts in Africa. It also has the relevance governance and oversight organs
in place to oversee the work, including a Scientific and Technical Advisory committee (STAC).
It should be noted that ANDI governance organs are continually reviewed and there is flexibility
to accommodate any specific need of the demonstration projects in terms of oversight.
The work of ANDI, and other organizations like the European Developing Country Clinical Trial
Partnership (EDCTP) suggest that this proposal is scientifically and technically feasible. It is
important to stress that that the capacity for innovation exists in Africa but what is missing is the
relevant coordination, financing and the political will to support the translation of research into
useful health products in Africa (4, 6, 7, 10, 11). The outcome of the call for proposals by ANDI
presents a direct evidence for the scientific feasibility of this proposal:
i) The identification and recognition of the first set of pan-African CoEs in health innovation
based on criteria and an open call for proposals. The resulting CoEs are now supporting
implementation of specific ANDI activities and will be part of the implementation of this
project and associated capacity building (1).
ii) Successful identification and initiation of projects through transparent call for proposals,
and funding of projects.
Potential risks associated with this proposal and how to mitigate them are as follows:
i) ANDI is presently being transition from WHO/TDR to UNOPS in Addis Ababa, after
initial hosting challenges at the United Nations Economic Commission for Africa
(UNECA). This risk is minimal because the transition of ANDI to UNOPS will be
finalized before the end this year 2013.
ii) Human capacity and funding to support the coordination and funding of
demonstration projects: The hope is that this proposal will be funded to be able
provide coordination and individual funding of the pipeline of demonstration projects.
iii) Lack of partners to support selected demonstration projects: this risk is minimal as
ANDI will seek missing and relevant expertise from around the world to support the
successful implementation of the projects. ANDI is already established key South
South and North South partnerships as part of it ongoing activities and will leverage
these as part of this project.
iv) Regulatory challenges in Africa: ANDI will engage with WHO prequalification,
regulatory harmonization initiatives in Africa and stringent regulatory bodies to
address this challenge. As part of this initiative ANDI will also support training and
capacity building for companies and regulators that will be involved on the project.
(Approximately 500 words)
10. Reasons for proposing:
(Provide details if any priority setting and/or selection criteria that has underpinned the consideration to take up this area of technology for development.)
Our proposal presents a holistic and sustainable approach to the health needs of
developing countries. As indicated earlier, the establishment of ANDI and its objectives are
aligned with the GSPoA and recognized by World Health Assembly through WHA62.16, 2009.
In her address to the 66th World Health Assembly in Geneva in Geneva, the Chairperson of the
African Union (AU), Madam Zuma, highlighted ANDI as very important initiation for Africa
and the entire world. This underscores the leading role that ANDI can in the coordination and
financing of R&D in Africa.
Furthermore, a number of international and pan-African reports and resolutions such as the
Commission on Health Research for Development [12], the Accra Plan of Action [13], the Abuja
declaration of 2001 by African leaders [14], and a number of African Ministerial Declarations
[15,16], have stressed the need to support health R&D capacity and coordination for diseases that
are predominant in developing countries especially Africa as well as financing. The resolution
of the World Health Assembly to identify and implement demonstration projects and R&D
observatory presents a real opportunity (WHA66.22). This proposal therefore presents a
unique opportunity for the international community and African government to support the
coordination and financing of R&D and innovation through this critical WHO process.
(Approximately 200 words)
11. Who could potentially develop the technology/carry out the research?
(Provide known details: individual researcher? Group of researchers? Research/coordination organization including PDPs? Group of research organizations working together? Combination of these; What would be the process of selection of developers?) To be successful, a publicly driven product R&D project will require a network or
consortium of partners including public and private agencies, PDPs or individual with
expertise in the various parts of the product R&D value chain, working together to
implement the project. The project will be structured such that transition from one phase
of the value chain to another will be seamless and necessary contractual agreement,
including IP arrangements will be established early in the process to avoid
misunderstanding. ANDI will help in establishing this consortium with necessary
expertise using its network of Centres of Excellence as well as North South and South
South partners. Furthermore, ANDI can also implement new calls to augment
available projects or assuming that no demonstration projects are identified at this
stage. In all cases, ANDI CoEs with relevant expertise will help to fill gaps and
implement R&D.
(Approximately 100 words)
12. Who could potentially manufacture the final product?
Multinational company? Local production? Joint venture? How the decision will be made about the producer?
Transitioning a product from research to manufacture is critical to ensuring access. This is one of
the roles of this coordination effort, which will address issues like downstream manufacturing
partners and the necessary contractual arrangements. Indeed, ANDI is already in discussion with
a number local, regional and multinational companies regarding manufacturing and technology
transfer in Africa. This process will be difficult to handle by individual researchers or
institutions in Africa. ANDI has established a mechanism that supports the managements of this
critical interface in a way that de-links R&D cost from the cost of final products (Fig 2). The
approach considers a granting mechanism for R&D, while the downstream part of
manufacturing, distribution and access requires a mix of grants making, technology transfer,
social and joint venture approaches. This will bring about sustainability and access to final
product while creating opportunity for technology transfer through South South and North South
partnerships. The public procurement incentive will also be used to incentivize the downstream
side of the value chain.
(Approximately 100 words)
13. What could be the role of WHO, if any, in this demonstration project to bring
this venture to fruition? WHO (AFRO and HQ) is a member of the ANDI Board and is represented on the ANDI STAC
as observer. This makes WHO an integral part of the ANDI work. Furthermore, ANDI have
ongoing collaboration with various WHO departments, for example, ANDI was
incubated by TDR, and ANDI will continue to work with TDR, if this proposal if supported.
ANDI can work with WHO/AFRO to establish a joint technical committee made of ANDI
STAC, AFRO ACHR and AU for the purposes of reviewing progress towards the
implementation of the demonstration projects, as needed.
The WHO Essential Medicines department (WHO/EMP), which now houses the Public Health,
Innovation and Intellectual property (PHI) as well as the Prequalification and Regulatory
Strengthening units will be important partners in this project. Indeed, ANDI is already working
with this department at different levels, including through an international consortium of partners
to support the AU in the implementation of the Business Plan for the Pharmaceutical
Manufacturing Plan for Africa (PMPA). Indeed, ANDI, WHO, UNAIDS, UNIDO and AfDB are
members of this consortium established by the AU. Support for the regulatory work on the
demonstration project and the associated capacity building will involve the WHO/EMP.
Furthermore, ANDI will work with the technology transfer WHO as well as the R&D
Observatory being established by WHO. (Approximately 200 words)
14. Please outline a timeframe and projected milestones for the project covering
the first 5 years. This should also highlight the immediate actions that need to be taken?
Assuming the relevant funds are available after World Health Assembly in May 2014, the
timelines and projected milestones for this coordination and financing role over 5 years are as
follows:
1) ANDI will meet with the leaders of the approved demonstration or other R&D projects
from Africa to discuss and clearly define project milestones, timelines, missing expertise
to achieve project objectives, target product profiles and go/no criteria for the projects.
The meeting will also discuss resource needs, review/reporting processes and project
agreement. Timeline for this is June 2014 till October 2014.
2) In parallel with action 1, ANDI will initiate the recruitment of relevant staff to support
the implementation of the pipeline of projects, including the establishment of relevant
partnerships. Timeline for this will be June 2014 – December 2014.
3) Project and partnerships agreement in place. Timeline: September 2014 – February 2015.
4) Implementation kick off meeting: this will be a collective meeting of all demonstration
projects to discuss the pipeline of projects or portfolio. All relevant partners will be
invited to this meeting including WHO and other interested parties. Timeline for this will
be March 2015.
5) Ongoing annual STAC meeting to review progress starting December 2014 till 2018,
followed by governance meetings.
6) Targeted call for proposal to strengthen and achieve optimal portfolio of projects for
delivery of the objectives of demonstration projects, if required after STAC reviews.
Timeline January 2015 - 2018.
7) Ongoing field Monitoring and Evaluation of projects by secretariat staff, consultants etc:
Timeline March 2015 – 2018
8) Ongoing report to World Health Assembly through WHO. Timeline January 2015 - 2018
9) Ongoing capacity building activities linked to demonstration projects including
regulatory support. Timeline March 2015 – December 2018
10) Ongoing development of critical and shared technologies such as new compound
collection and screens. Timeline March 2015 – December 2018
11) Registration of a product by December 2018 from demonstration projects
12) Over 100 Africans will be trained and 5 institutions (public and private sectors)
strengthened based on concrete projects in various parts of the R&D value chain,
portfolio management, project and finance management.
(Approximately 200 words)
15. What is the intellectual property (IP) landscape relative to this project? Is there any IP, e.g. patents that need to be licensed in to be able to develop and market the product in developing countries? How would IP and related intellectual assets, including knowhow, proposed to be managed in this project?
IP management and licensing issues are important parts of the coordination. Experience
shows that every product R&D project will have unique characteristics regarding IP
employed in the development of the product, as well as partnership arrangements. ANDI has
developed a draft IP strategy with the support of WIPO and UNDP which will be ratified by
the Board in due course. The basic premise of this strategy is that ANDI will use IP, where
appropriate, to support the advancement of products for public health access in developing
countries. IP will typical reside with the institutions or agency that developed them but ANDI
will seek appropriate licence to enable continued and unhindered development and public
health access for the product in developing countries. ANDI will also facilitate the
development of IP or patents, in instances where it will advance access to products for
diseases that disproportionately affect developing countries. ANDI will also promote the use
of TRIPS flexibilities to support access to products.
(Approximately 400 words)
16.* What would be the strategy to ensure access to the product once it is developed? (Access is an important dimension of these demonstration projects, it is important for
the projects to begin with the end in mind, explain how this project would deliver the technologies to the needy patients i.e. price and affordability; modes of supply; storage; prescription; dispensing; and compliance; WHO will develop guiding principles for ensuring access to any products coming out of the demonstration projects)
ANDI will adhere to any WHO guiding principles for ensuring access to any product
coming out of this process. In addition, the following modalities will be considered as
part of the project agreements to ensure access: i) In addition, ANDI will engage with
African governments, development agencies, international organizations, NGOs and
Foundations to secure procurement of the products resulting from this project for the
poor populations of Africa; ii) ANDI will also ensure that appropriate pricing for the
products that result from this process are agreed ahead of time and that products sold
through the public and private sector market meet these pricing guidelines; iii) as part
of the work of ANDI, appropriate training and partnership concerning supply chain
management and delivery will be implemented in preparation for the arrival of new
product.
(Approximately 400 words)
17. How could the project be financed paying particular attention to the need to
demonstrate new and innovative forms of financing? Also provide an estimated cost of the project.
This proposal assumes that a certain level of financial commitment will be provided by
WHO through its member states to kick-start the implementation of selected demonstration
projects. As indicated above, this commitment can be operationalized through the
establishment of pooled financing mechanism where countries can contribute into or through
special airline or tobacco taxes. These funds can be hosted and managed regionally and/or
globally in a professional and self-sustaining manner. From these funds, regional R&D
activities can be financed through an appropriate coordinating body. Regional development
banks such as the African Development Bank or an appropriate WHO or UN Trust Fund can
be established for such funds, from which specific project funds can be disbursed at the
request of the coordinating body. The fund can provide grant money for the R&D part of the
demonstration projects and also promote various venture approaches or guaranteed loan for
manufacturing and access. In addition, government or international guarantee for
procurement of finished product would be helpful, assuming all conditions are met. This
approach will promote technology transfer, South South and North South collaboration to
support sustained local production and access of finished product.
A realistic budget for this proposal will be defined once the number and types of
demonstration project that will be supported under this coordination mechanism is
established. In the time, considering that ANDI has a very slim structure, the possible
cost of coordination without direct funding for project can range from USD1 to 2 Million
per annum over five years.
(Approximately 200 words)
18. How could the project be governed and coordinated paying particular
attention to the need to demonstrate better way of coordination? This proposal is focusing on governance, coordination and financing of demonstration and R&D
projects in Africa through the use of existing ANDI structure (Fig 4) consisting of Board,
Secretariat, STAC and host agency .
ANDI Board: The Board is a ministerial level board and currently consists of 12 members from
among its key stakeholders including representatives of ministries of health, science and
technology and finance from the five regions of Africa.
ANDI Secretariat: The Secretariat includes the central office of ANDI, its sub-regional hubs
and staff responsible for the implementation of all ANDI activities under the leadership of an
Executive Director.
Host agency in Africa: United Nations Office for Project Services (UNOPS) has been selected
by the ANDI Board as the new host agency for ANDI and contractual arrangement between
WHO and UNOPS is being finalised to this effect
STAC: The STAC is comprised of experts with a track record in various aspects of health
product innovation and the R&D value chain. STAC members are independent experts acting in
an individual and personal capacity. They provide technical advice to the ANDI Board and the
ANDI Secretariat.
Figure 4: Governance structure of ANDI
(Approximately 200 words)
19. Have any donor agencies/governments already indicated interest in supporting the project?
The work of ANDI is presently supported with funding from the European Union,
WHO/TDR, Nigeria, the African Development Bank including through Trust Funds from
South Korea and Brasil.
(Approximately 200 words)
References:
1) Nwaka et al. Analysis of pan-African Centres of excellence in health innovation
highlights opportunities and challenges for local innovation and financing in the continent. BMC International Health and Human Rights 2012, 12:11 Page 2 of 15
2) World Health Organization: World Health Report 2004. Geneva: 2004. http://www.who.int/whr/2004/en/report04_en.pdf.
3) Murray CJ, Lopez AD: Mortality by cause for eight regions of the world:Global Burden of Disease Study. Lancet 1997, 349:1269–1276.
North
hub
Central
hub
South
hub
East
hub
West
hub
ANDI Office
Advocacy
IP/technology transfer
R&D coordination
STAC
Fund
Board
Executive
committee
(EC)Finance
Committee
(FC)
Board
North
hub
Central
hub
South
hub
East
hub
West
hub
ANDI Office
Advocacy
IP/technology transfer
R&D coordination
STAC
Fund
Board
Executive
committee
(EC)Finance
Committee
(FC)
North
hub
Central
hub
South
hub
East
hub
West
hub
ANDI Office
Advocacy
IP/technology transfer
R&D coordination
STAC
FundFund
Board
Executive
committee
(EC)Finance
Committee
(FC)
Board
4) Strategic Business Plan for ANDI: (http://www.andi-africa.org/images/stories/docs/Business%20Plan.pdf)
5) http://blogs.worldbank.org/africacan/how-does-africa-fare-findings-from-the-global-
burden-of-disease-study 6) Nwaka S. et al. (2010) Developing ANDI: A Novel Approach to Health Product R&D in
Africa. PLoS Med 7(6): e1000293. doi:10.1371/journal.pmed.1000293% 7) Simiyu K, Daar AS, Singer PA: Global health. Stagnant health technologies in Africa.
Science 2010, 330:1483–1484. 8) Trouiller P et al. (2002) Drug development for neglected diseases: a deficient market and
a public-health policy failure. Lancet. 2002 Jun 22;359(9324):2188-94. 9) WHO WHA 61.21 2008 http://apps.who.int/gb/ebwha/pdf_files/A61/A61_R21-en.pdf) 10) Irikefe V et al: The view from the front line - Africa’s nations are achieving some success
in building their science capacity, but the foundations remain unsteady. Nature 2011, 474:556–559.
11) NEPAD and COHRED: Strengthening Pharmaceutical innovation in Africa. 2010. 12) Commission on Health Research for Development: Health research. New York: Essential
Link to Equity in Development. Oxford University Press; 1990. 13) OECD: The Paris Declaration on Aid Effectiveness and the Accra Agenda for Action
2005/2008. Accra; 2008. 14) United Nation: Abuja declaration on HIV/AIDS. Tuberculosis and other related
infectious diseases, OAU/SPS/ABUJA/3. Abuja:; 2001. 15) African Ministerial Council on Science & Technology: Resolutions f The Second African
Ministerial Conference On Science And Technology. Dakar: 2005. 16) World Health Organization Regional Office for Africa: The Algiers Declaration. Algiers:
Ministerial Conference on Research for Health in the African Region; 2008.